drugset / Trial / NCT00868452

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

NCT00868452

Phase 3 Completed 348 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.

Timeline

Start
2009-04
Primary completion
2011-12
Completion
2012-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 60 mg
Comparator Divalproex Sodium Small molecule
Comparator Lithium Unknown

Indications